Nanobiotix reports final melanoma cohort results for radioenhancer combination
Nanobiotix ($NANO) reported updated Phase 1 results in 24 heavily pretreated patients with advanced cutaneous melanoma resistant to anti-PD-1 therapy. Its JNJ-1900, also called NBTXR3, was injected into a tumor before radiotherapy and subsequent checkpoint-inhibitor treatment. Ten patients responded, giving a 41.7% response rate, including four complete responses; disease control was reported in 75%. Median overall survival reached 17.8 months and median progression-free survival was 6.9 months.
0